| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5665772 | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004973 | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jul, 2016
(7 years ago) | |
|
US6004973 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jan, 2017
(7 years ago) | |
| US7297703 | NOVARTIS | Macrolides |
Dec, 2019
(4 years ago) | |
| US7741338 | NOVARTIS | Macrolides |
Dec, 2019
(4 years ago) | |
|
US5665772 (Pediatric) | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar, 2020
(4 years ago) | |
|
US7297703 (Pediatric) | NOVARTIS | Macrolides |
Jun, 2020
(3 years ago) | |
| US8778962 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(2 years ago) | |
| US8436010 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(2 years ago) | |
|
US8778962 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 8 months ago) | |
|
US8436010 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 8 months ago) | |
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(1 year, 6 months from now) | |
|
US8410131 (Pediatric) | NOVARTIS | Cancer treatment |
May, 2026
(2 years from now) | |
| US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(4 years from now) | |
Afinitor is owned by Novartis.
Afinitor contains Everolimus.
Afinitor has a total of 14 drug patents out of which 11 drug patents have expired.
Expired drug patents of Afinitor are:
- US6004973
- US6004973*PED
- US7297703
- US7741338
- US5665772*PED
- US7297703*PED
- US8778962
- US8436010
- US8778962*PED
- US8436010*PED
- US5665772
Afinitor was authorised for market use on 09 July, 2010.
Afinitor is available in tablet;oral dosage forms.
Afinitor can be used as treatment of patients with progressive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic, treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected., treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole, treatment of solid excretory system tumors; advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib.
Drug patent challenges can be filed against Afinitor from 26 October, 2014.
The generics of Afinitor are possible to be released after 01 July, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-724) | Feb 26, 2019 |
| Orphan Drug Exclusivity(ODE-108) | Feb 26, 2023 |
| Orphan Drug Exclusivity(ODE-24) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-11) | May 05, 2018 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-630) | Oct 29, 2013 |
| New Indication(I-655) | Jul 20, 2015 |
| New Indication(I-650) | Apr 26, 2015 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
| Pediatric Exclusivity(PED) | Oct 26, 2015 |
| New Indication(I-638) | May 05, 2014 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 26 October, 2014
Market Authorisation Date: 09 July, 2010
Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Treatment of ...
Dosage: TABLET;ORAL
AFINITOR family patents
